TABLE 5.
Frequency distributions of GCV IC50s for recent clinical isolates using the ACTG consensus protocol
| GCV IC50 (μM) | No. of assays with IC50 at each GCV concn
|
|||||
|---|---|---|---|---|---|---|
| CMV 1a | CMV 2 | CMV 3 | CMV 4 | CMV 5 | CMV 6 | |
| ≤1.5 | 2 | 1 | 2 | |||
| >1.5–3.0 | 3 | 2 | ||||
| >3.0–6.0 | 2 | 2 | 1 | 1 | 7 | |
| >6.0–12 | 2 | 2 | 2 | |||
| >12–24 | 2 | 2 | 2 | |||
| >24–48 | 2 | 2 | 1 | 1 | ||
| >48–96 | 4 | 1 | 1 | 3 | ||
| >96 | 1 | 10 | 1 | 8 | ||
| Total no. of assays | 12 | 10b | 12 | 12 | 12 | 12 |
| Median IC50 | 22.94 | 2.97 | >96 | 11.31 | 4.13 | >96 |
| No. (%) resistant | 8 (67) | 1 (10) | 11 (92) | 6 (50) | 3 (25) | 12 (100) |
a
CMV 1 to 6 were not plaque purified.
b
Data not submitted by two laboratories.